Form 4: Director Jonathan Lim Receives Stock Options at Boundless Bio

Boundless Bio, Inc. director Jonathan E. Lim was granted 48,000 stock options as part of his compensation package.

Summary

• Director Jonathan E. Lim received a grant of 48,000 stock options on June 15, 2026.
• The options have an exercise price of $1.40 per share.
• The options are set to expire on June 14, 2036.
• Vesting occurs in equal monthly installments over 12 months, subject to continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the director's continued service on the board.

Future Outlook

The options vest over a 12-month period starting June 15, 2026, or upon the next annual meeting if it occurs before June 15, 2027.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of key leadership.

Comparison to Industry Standards

• The use of monthly vesting schedules for director equity is consistent with standard corporate governance practices for small-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised.

Next Steps

• Vesting of options over the next 12 months.

Key Dates

Keywords

Boundless Bio, BOLD, Form 4, Insider Trading, Stock Options, Director Compensation